09:00 Opening remarks by James Nurton, managing editor, Managing IP
09:10 Final preparations for the sunrise period: to opt or not to opt?
- How to undertake a successful opt-out and adjustments to your filing strategy
- Practical steps and strategies for the next 3-6 months
- Will the UK stay or go post-Brexit?
Ulrich Blumenröder, partner, Grünecker
Wolfgang Neubeck, partner, Grünecker
09:55 Procedures to obtaining evidence of an infringement
- The rules of evidence in the UPC
- Drawing comparisons between different systems in Europe
- Analysing the procedural advantages of each jurisdiction
Caroline Casalonga, partner, Casalonga
Ewan Nettleton, senior patent counsel, Novartis
Gwennhaël Le Roy, partner, French and European Patent Attorney, Casalonga
10:40 Coffee break and networking
11:00 Litigating and licensing SEPs in Europe
- Questions unanswered by Unwired Planet
- French decisions and approaches Huawei v ZTE
- Availability of final injunctions in France and the UK for SEP infringements
- SEP litigation in the UPC – who will benefit and who will lose out?
Alex Brodie, partner, Gowling WLG (moderator)
Adrian Howes, senior legal counsel, Nokia
Catherine Menes, patent management services and skills, Peugeot Citroen
Céline Bey, partner, Gowling WLG
11:45 UK Courts get down to business: application of discretion and flexibility to resolve commercial uncertainty
- Arrow declarations to weed out thickets of divisionals
- Developments in worldwide discretionary telecoms declarations
- Impact of Supreme Court in Pemetrexed on declarations of non-infringement
Pete Damerell, partner, Powell Gilbert
Zoe Butler, partner, Powell Gilbert
12:30 How can defendants use the UPC to revoke patents?
- What litigation will exist in national courts and EPO in parallel to the UPC?
- Pros and cons
- Patent litigation and forum shopping at a cross-EU level
- Will the UPC system be able to apply the bifurcation principle?
Marianne Schaffner, partner, Dechert
Adrien Renoult, IP corporate counsel, Nokia
13:15 Lunch and networking
14:10 Life sciences and pharma litigation
- Life sciences and the unitary patent package: will the system be used and if so how?
- Taking advantage of second medical use patents and data: enough is enough
- Patent protection strategies involving divisionals: have we gone too far?
Dominic Adair, partner, Bristows (moderator)
Denise Hirsch, director of protection and institutional partnerships, Inserm Transfert
Lorenz Kallenbach, corporate patent counsel, Merck
Gemma Barrett, senior associate, Bristows
14:55 Interplay between US filing and the introduction of the UPC
- The US view of UPC impact
- Coordinating EU and US patent strategies
- Crucial differences between US inter partes reviews (IPRs) and revocation actions in Europe
Edward Kelly, partner, Ropes & Gray (moderator)
Bruce Elder, director intellectual property & licensing, Integrated Device Technology
Regina Penti, counsel, Ropes & Gray
15:40 Coffee break and networking
16:00 Case study: efficiently protecting your software-related inventions: the do’s and don’ts
- Which software inventions can be protected by European patents?
- What are the important issues when drafting a European patent application for a software-related invention?
- What are the crucial questions the EPO examiner will ask you?
- What remedies are available to you if your software-related patent application is refused at first instance
Philip Cupitt, partner, Finnegan Henderson Farabow Garrett & Dunner
Yannis Skulikaris, director operations, information & communications technology, European Patent Office
16:45 Long-term implications of Brexit
- Forecast post-2019: what can you expect?
- How will existing rights be affected?
James Nurton, managing editor, Managing IP (moderator)
Marcus Southerden, vice president, global IP, Barclays
Maximin Gourcy, intellectual property manager, DS Smith
17:30 Close of conference